Spironolactone-related inhibitors of type II 17β-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities
Authors:
- Van Luu-TheVLVan Luu-The
- Gilles LeblancGLGilles Leblanc
- Patricia NoëlPNPatricia Noël
- Esther BretonEBEsther Breton
- Fernand LabrieFLFernand Labrie
- Donald PoirierDPDonald Poirier
- 1 June 1999
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 7 (6) , 1013-1023
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Characteristics of human types 1, 2 and 3 17β-hydroxysteroid dehydrogenase activities: Oxidation/reduction and inhibitionThe Journal of Steroid Biochemistry and Molecular Biology, 2000
- Intracellular regulation of 17β-hydroxysteroid dehydrogenase type 2 catalytic activity in A431 cellsJournal of Endocrinology, 1997
- 17 -Hydroxysteroid dehydrogenase: inhibitors and inhibitor designEndocrine-Related Cancer, 1996
- Aromatase inhibitors in the treatment of breast cancerThe Journal of Steroid Biochemistry and Molecular Biology, 1994
- Characterization of 17β-Hydroxysteroid Dehydrogenase Activity and mRNA Abundance in Human Meningioma TumorsNeuroendocrinology, 1994
- 11β-Amidoalkyl estradiols, a new series of pure antiestrogensThe Journal of Steroid Biochemistry and Molecular Biology, 1992
- Distribution of 17β-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissuesThe Journal of Steroid Biochemistry and Molecular Biology, 1992
- The role of endocrine therapy in primary breast cancerJournal of Steroid Biochemistry, 1990
- Complete amino acid sequence of human placental 17β‐hydroxysteroid dehydrogenase deduced from cDNAFEBS Letters, 1988
- Addition of Alkanethiolic Acids to Δ1,4-3-Oxo- and Δ4,6-3-Oxosteroids1Journal of the American Chemical Society, 1959